Pharmaco-invasive strategy with half-dose recombinant human prourokinase (PHDP): One-year outcomes

Asian J Surg. 2023 Jun;46(6):2645-2646. doi: 10.1016/j.asjsur.2022.12.150. Epub 2023 Jan 10.

Authors

Chao Jiang¹, Jie Dou¹, Yun-Fei Ji², Dong-Lei Luo³

Affiliations

¹ Chengde Medical University, Chengde, Hebei, China.
² Chengde Central Hospital/Second Clinical College of Chengde Medical University, Chengde, Hebei, China. Electronic address: jiyunfei81@163.com.
³ Chengde Central Hospital/Second Clinical College of Chengde Medical University, Chengde, Hebei, China. Electronic address: dongleiluocn@aliyun.com.

PMID: 36635174
DOI: 10.1016/j.asjsur.2022.12.150

No abstract available

Keywords: Follow up; Primary percutaneous coronary intervention; Recombinant human prourokinase.

Publication types

Letter